Registration for a live webinar on 'The role of T cells in COVID from asymptomatic to severe outcomes' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Fundamental aspects
-
1. Inflammation and tissue homeostasis
- Prof. Herman Waldmann
-
2. Introduction to the immune system
- Prof. Herman Waldmann
-
3. Hematopoiesis: the making of an immune system
- Prof. Paul J. Fairchild
-
4. Inflammation: purposes, mechanisms and development
- Prof. Pietro Ghezzi
-
5. Phagocytosis
- Dr. Eileen Uribe-Querol
-
6. Regulated cell death mechanisms and their crosstalk with the immune system 1
- Dr. Luis Alberto Baena-Lopez
-
7. Regulated cell death mechanisms and their crosstalk with the immune system 2
- Dr. Luis Alberto Baena-Lopez
- Innate immunity
-
11. Cells of the innate immune system
- Prof. Kevin Maloy
-
12. Microbial recognition and the immune response
- Dr. Dana Philpott
-
13. Toll-like receptor signalling during infection and inflammation
- Prof. Luke O'Neill
- Intercellular mediators
-
14. Chemokines
- Dr. James E. Pease
-
15. Cytokines
- Prof. Iain McInnes
-
16. IL-1 family cytokines as the canonical DAMPs of the immune system
- Prof. Seamus Martin
-
17. Glycoimmunology
- Prof. Paula Videira
- Adaptive immunity B cells
-
20. Antigen recognition in the immune system
- Prof. Herman Waldmann
-
21. B cell biology
- Prof. Richard Cornall
-
22. Antibody structure and function: antibody structure
- Dr. Mike Clark
-
23. Antibody structure and function: antibody function
- Dr. Mike Clark
-
24. Antibody genes and diversity
- Dr. Mike Clark
-
25. In vivo antibody discovery and hybridoma technology
- Prof. Dr. Katja Hanack
-
26. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
28. The immunobiology of Fc receptors
- Prof. Mark Cragg
-
29. Immunoreceptors
- Prof. Anton van der Merwe
-
30. Affinity, avidity and kinetics in immune recognition
- Prof. Anton van der Merwe
- Adaptive immunity T cells
-
31. The thymus and T cell development: a primer
- Prof. Georg Holländer
-
32. Lineage decisions in the thymus: T cell lineage commitment
- Prof. Bruno Silva-Santos
-
33. Lineage decisions in the thymus: αβ and γδ T cell lineages
- Prof. Bruno Silva-Santos
-
34. CD4 T cell subsets
- Dr. Brigitta Stockinger
-
35. Cytotoxic T lymphocytes
- Prof. Gillian Griffiths
-
36. Gamma delta T-cells
- Prof. Bruno Silva-Santos
-
37. Tfh and Tfr cells
- Prof. Luis Graca
-
38. Tissue resident memory T cells (TRM)
- Dr. Marc Veldhoen
-
39. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
- The importance of the MHC in immunity
-
40. The MHC and MHC molecules 1
- Prof. Jim Kaufman
-
41. The MHC and MHC molecules 2
- Prof. Jim Kaufman
-
42. Natural killer cells
- Dr. Philippa Kennedy
-
44. NK cells in viral immunity
- Prof. Lewis Lanier
- Lymphocyte activation
-
45. Signal transduction by leukocyte receptors
- Dr. Omer Dushek
-
46. Immunological memory 1
- Prof. David Gray
-
47. Immunological memory 2
- Prof. David Gray
-
48. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
- Major cellular partners in immunity
-
49. The mononuclear phagocyte system - tissue resident macrophages: distribution and functions
- Prof. Emeritus Siamon Gordon
-
50. The mononuclear phagocyte system: tissue resident macrophages - activation and regulation
- Prof. Emeritus Siamon Gordon
-
51. Dendritic cells: professional antigen presenting cells
- Prof. Paul J. Fairchild
-
52. Mucosal immunology
- Prof. Daniel Mucida
- Immunological tolerance and regulation
-
53. Self-tolerance
- Prof. Herman Waldmann
-
54. Tolerance and autoimmunity
- Prof. Emerita Anne Cooke
-
55. The balance between intestinal immune homeostasis and inflammation
- Prof. Dr. Janneke Samsom
- Translational immunology - immune deficiency
-
56. Primary immunodeficiency disorders
- Dr. Smita Y. Patel
-
57. Changes in innate and adaptive immunity during human ageing 1
- Dr. Roel De Maeyer
-
58. Changes in innate and adaptive immunity during human ageing 2
- Dr. Roel De Maeyer
-
59. The aging immune system
- Prof. Ana Caetano
- Translational immunology - protection against pathogenic microbes
-
60. Immune responses to viruses
- Prof. Paul Klenerman
-
61. HIV and the immune system
- Prof. Quentin Sattentau
-
62. COVID-19: the anti-viral immune response
- Prof. Danny Altmann
-
63. Bacterial immune evasion
- Prof. Christoph Tang
-
64. The immunology underlying tuberculosis
- Prof. Thomas R. Hawn
-
65. Innate immunity to fungi
- Prof. Gordon D. Brown
-
66. Parasite immunity: introduction and Plasmodium
- Dr. Catarina Gadelha
-
67. Parasite immunity: Leishmania and Schistosoma
- Dr. Catarina Gadelha
-
68. Vaccination
- Dr. Anita Milicic
-
69. The history of vaccines 1
- Prof. Emeritus Anthony R. Rees
-
70. The history of vaccines 2
- Prof. Emeritus Anthony R. Rees
-
71. The history of vaccines 3
- Prof. Emeritus Anthony R. Rees
-
72. The science of vaccine adjuvants
- Dr. Derek O'Hagan
- Translational immunology - hypersensitivity, autoimmune disease and their management
-
73. Hypersensitivity diseases: type 1 hypersensitivity
- Prof. Herman Waldmann
-
74. Innate lymphoid cells in allergy
- Prof. Emeritus Shigeo Koyasu
-
75. Hypersensitivity diseases: type II-IV hypersensitivity
- Prof. Sara Marshall
-
76. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
77. Interleukin-17: from clone to clinic
- Prof. Leonie Taams
-
78. Autoimmunity and type 1 diabetes
- Prof. Emerita Anne Cooke
-
79. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
80. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
81. Monoclonal antibodies in haemato-oncology
- Prof. Mark Cragg
-
82. Therapeutic antibodies
- Dr. Geoffrey Hale
-
83. Neuroimmunometabolism
- Prof. Ana Domingos
-
84. The immunology of multiple sclerosis
- Dr. Joanne Jones
-
85. Understanding myasthenia gravis and advances in its management
- Prof. Henry J. Kaminski
-
86. The immunology underlying rheumatic diseases
- Dr. Hussein Al-Mossawi
-
88. Complement and lupus
- Prof. Marina Botto
-
89. Immune mechanisms in liver diseases
- Prof. Paul Klenerman
- Translational immunology - transplantation immunology
-
90. Principles of transplantation: overview of the immune response
- Prof. Emerita Kathryn Wood
-
91. Factors influencing outcomes in clinical transplantation 1
- Prof. Emerita Kathryn Wood
-
92. Factors influencing outcomes in clinical transplantation 2
- Prof. Emerita Kathryn Wood
- Translational immunology - cancer immunology
-
93. Cancer immunology
- Prof. Tim Elliott
-
94. Cancer immunotherapy
- Prof. Tim Elliott
-
95. Myeloid-derived suppressor cells in cancer
- Prof. Dmitry Gabrilovich
-
96. IL-2 in the immunotherapy of autoimmunity and cancer
- Prof. Thomas Malek
-
97. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
Printable Handouts
Navigable Slide Index
- Introduction
- Antibody structure
- Antibodies - nature's pro-drugs
- Key properties of antibodies relevant to therapy
- Antibodies are different from conventional drugs
- Treatment of sarcoma by serotherapy
- Conclusions from Hericourt and Richet
- Paul Ehrlich 1854-1915
- Modes of antibody therapy
- Problems with polyclonal antisera
- Making monoclonal antibodies
- Pros and cons of monoclonal antibodies
- Antibodies for cell depletion
- Genetic engineering of antibodies
- Chimeric antibodies
- Making chimeric antibodies
- Effector functions of anti-NP antibodies
- Humanised antibodies
- Making humanised antibodies by phage display
- Making phage antibodies
- Infection, replication and enrichment
- Pros and cons of phage antibodies
- Antibodies from transgenic mice
- Antibody nomenclature: source
- Immunogenicity of therapeutic Mabs
- Immunogenicity
- Factors influencing the antiglobulin response
- Some observations
- Increasing antibody affinity
- Antibodies for tumour therapy
- CD20 antigen
- CD20 and B cell development
- Phase III trial of rituximab in follicular lymphoma
- CD20 epitopes
- Type I and II antibodies
- Anti-CD20 antibodies
- Antibodies for immunomodulation
- Tumour necrosis factor (TNF)
- Physiology of TNF
- Phase III trial of infliximab in rheumatoid arthritis
- Anti-TNF antibodies
- CD52 antigen
- CD52 antigen structure
- Treatment with rat CD52 antibodies
- Treatment of lymphoma with alemtuzumab
- Alemtuzumab effectively suppresses relapses
- Change in disability after alemtuzumab treatment
- Phase III trial of alemtuzumab in multiple sclerosis
- Approval of antibodies and fusion proteins
- Therapeutic antibodies & fusion proteins
- Thank you
Topics Covered
- Why antibodies are so useful as drugs
- Antibody therapy
- The development of monoclonal antibodies
- Genetic engineering
- The problem of unwanted immunogenicity
- The importance of affinity
- Examples of antibodies for treatment of cancer
- Examples of antibodies for treatment of immunological diseases
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Hale, G. (2020, October 29). Therapeutic antibodies [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 25, 2024, from https://hstalks.com/bs/4433/.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Geoffrey Hale has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Immunology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello and welcome to this Henry Stewart Talk on the immune system.
I'm Geoff Hale and today I plan to tell you a bit about
the development and use of antibodies for treating a wide range of diseases,
starting right back in the 19th century and coming up to the present day.
0:19
First of all, just a little bit of recap about the antibody structure and what they are.
You'll remember that antibodies have got
two binding sites that comprise of two different chains,
the heavy chain and the light chain.
At the end of the heavy chain,
you've got the Fc region,
which is responsible for binding to molecules in the immune system,
that calls the effector function of the antibodies.
0:45
Normally antibodies circulate around the body in
large quantities and they are comparatively inert.
But when they encounter a pathogen,
say it's a bacterium or a virus,
they can bind to antigens on its surface
and that causes aggregation of the antibody Fc domains.
That greatly increases the affinity of their binding to complements or to
Fc receptors and it leads to activation of those physiological effector functions.
Aggregation of antibodies is a really important part of their function.
1:19
There's some key properties of antibodies which are
really important for using them in therapy.
First of all, their binding function.
They are exquisitely specific to their target and that makes them
really useful because they don't target unwanted things usually.
Because they've got two binding sites,
they can hang on to antigens really tightly.
That is what we call avidity.
Then the effector function, as I've mentioned,
antibodies can activate complements,
they combine Fc receptors and that can lead to killing of cells and targets,
whether they're viruses or bacteria.
Thirdly, antibodies have a long half-life in the blood.
That's because they bind to another type of
Fc receptor called FcRN found in the liver and other cells.
It enables the antibody to be recycled back into
the circulation so that it survives perhaps for a month on average,
very useful feature if you use antibodies as drugs
because it means they don't have to be administered very frequently.
But antibodies are different from conventional drugs.